Breast Cancer Now media statements
We respond to new study into early-stage breast cancer treatment in UK during initial months of COVID-19 pandemic
Responding to a new study into the treatment of early breast cancer in the UK, between March and May 2020, led by the University of Manchest...
We welcome introduction of new treatment method for HER2 positive breast cancer by NHS England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times: February 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now said:
We welcome the approval of trastuzumab deruxtecan for use on the Cancer Drugs Fund
The National Institute for Health and Care Excellence (NICE) has today - 20 April 2021 - announced its decision to recommend breast cancer d...
We respond to the Clinical Radiology UK Workforce Census 2020 Report from The Royal College of Radiologists
The Royal College of Radiologists' (RCR) latest Clinical Radiology UK Workforce Census 2020 Report reveals the significant challenges facing...
We respond to NHS England breast cancer waiting times: March 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NHS Breast Screening Programme Statistics for Scotland 2017/18 to 2019/20
Mia Rosenblatt, Associate Director of Evidence, Policy and Influencing at Breast Cancer Now, said:
We respond to the announcement of more than £25m being invested in diagnostic equipment for NHS Wales
Mia Rosenblatt, Associate Director of Evidence, Policy and Influencing at Breast Cancer Now, said:
We respond to government funding announcement for early career researchers supported by charities
Responding to the Department for Business, Energy and Industrial Strategy's (BEIS) announcement of funding for early career researchers supp...
We respond to a new clinical trial into olaparib use for women with high risk HER2 negative primary breast cancer with altered BRCA genes
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to new figures from Cancer Research UK showing thousands fewer breast cancer patients started treatment in the last year in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to POLQ inhibitors identified as a new class of targeted drugs for cancers with BRCA mutations
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said: